

**SOMETHING
BETTER
THAN HOPE**

**GWG Recommendations for Applications
Submitted to the CLIN Program**


Gil Sambrano

Vice President
Portfolio Development and Review


November 23, 2021

CIRM
CALIFORNIA STEM CELL AGENCY

Clinical Stage Programs



CLIN 1



CLIN 2




CLIN 3

2021/22 Clinical Budget Status

Annual Allocation: \$162 million

- Amount Requested Today
- Approved Awards
- Unused Balance

Amounts are shown in millions



Review Criteria

1. Does the project hold the necessary significance and potential for impact? (i.e., what value does it offer; is it worth doing?)
2. Is the rationale sound? (i.e., does it make sense?)
3. Is the project well planned and designed?
4. Is the project feasible? (i.e., can they do it?)
5. Does the project address the needs of underserved communities?

Scientific Scoring System for Clinical Applications

- **Score of “1”**

Exceptional merit and warrants funding.

May have minor recommendations and adjustments that do not require further review by the GWG

- **Score of “2”**

Needs improvement and does not warrant funding at this time but could be resubmitted to address areas for improvement.

GWG should provide recommendations that are achievable (i.e., “fixable changes”) or request clarification/information on key concerns.

- **Score of “3”**

*Sufficiently flawed that it does not warrant funding and the same project should not be resubmitted **for at least 6 months.***

Applications are scored by all scientific members of the GWG with no conflict.

Elements in CIRM Application Review

- **Addressing the Needs of Underserved Communities**
 - This section describes the applicant's plan for outreach and enrollment of a diverse patient cohort that accounts for racial, ethnic and gender diversity
 - The section is evaluated as part of the overall project and incorporated into the scientific merit score (1, 2 or 3)
- **Diversity, Equity and Inclusion**
 - This section describes how the applicant team incorporates diverse perspectives and experiences to improve the project through the composition of the team and/or any other approaches
 - This section is evaluated and scored by patient advocate/nurse members of the Board (appointed to the GWG) and shown in the DEI score (0-10)

CLIN1-12865: A CAR-T Cell Therapy for B Cell Malignancies

Therapy	Chimeric antigen receptor (CAR) T cell therapy
Indication	B cell malignancies (chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia)
Goal	Submission of IND to the FDA
Funds Requested	\$4,130,260 (co-funding: \$858,722)

Maximum funds allowable for this category: \$6,000,000

CLIN1-12865: Background Information

Clinical Background: B cell malignancies include leukemias and lymphomas that have a poor prognosis or have a significant impact on quality of life. Lack of tolerable, and durable therapies for patients (particularly for recurring or refractory disease) represents an unmet need.

Value Proposition of Proposed Therapy: The proposed therapy utilizes a target, ROR1, with high specificity in B cell malignancies and solid tumors such as breast, lung and colon. It offers the possibility of a cure for patients with B cell malignancies and possible expansion to solid tumors in the future.

Why a stem cell project: The therapeutic candidate acts on cancer stem cells.

CLIN1-12865: Similar CIRM Portfolio Projects

Application/ Award	Project Stage	Project End Date	Indication	Candidate	Mechanism of Action
CLIN2	Phase 1b/2a clinical trial	Mar 2022	B cell malignancies	Monoclonal antibody	Monoclonal antibody targeting ROR1 combined with Bruton Tyrosine Kinase Inhibitor, Ibrutinib.
CLIN2	Phase 1 clinical trial	May 2022	B cell malignancies (recurrent or refractory)	CAR-T cell therapy	CAR- T cell therapy targeting combination of CD19 and CD22 antigens.

CLIN1-12865: Previous CIRM Funding to Applicant Team

Project Stage	Indication	Project Outcome	Project Duration	Award Amount	Milestones/Aims
Translational (Closed)	Hematologic malignancies	Conduct pre-IND meeting w/ FDA	Oct 2017 – Feb 2021	\$5,795,584	M1-M2: GMP manufacture of product and preclinical testing in patient-derived xenograft models to assess tolerance and efficacy (Achieved on time) M3: Conduct pre-IND meeting with FDA (Achieved with delay)

CLIN1-12865: GWG Review

GWG Recommendation: Exceptional merit and warrants funding

Scientific Score	GWG Votes
1	9
2	5
3	0

DEI Score: 9.5

CIRM Team Recommendation: Fund (concur with GWG recommendation)

CIRM Award Amount: \$ 4,130,260*

*Final award shall not exceed this amount and may be reduced contingent on CIRM's final assessment of allowable costs and activities.